Government panel offers strongest recommendation for PrEP to prevent HIV

The US Pre­ven­tive Ser­vices Task Force (USP­STF) pub­lished its strongest rec­om­men­da­tion that clin­i­cians should pre­scribe pre-ex­po­sure pro­phy­lax­is (PrEP) with ef­fec­tive an­ti­retro­vi­ral ther­a­py to peo­ple at in­creased risk of HIV ac­qui­si­tion.

The rec­om­men­da­tions in JA­MA on Tues­day came as part of an up­date to a 2019 re­view, and USP­STF gave its bless­ing to oral PrEP, which is as­so­ci­at­ed with de­creased risk of ac­quir­ing HIV in­fec­tion com­pared with place­bo or no PrEP. USP­STF added that Gilead’s De­scovy was non-in­fe­ri­or to its Tru­va­da brand and that the in­jectable cabote­gravir (Vi­iV Health­care’s Apre­tude) re­duced the risk of HIV in­fec­tion com­pared with Tru­va­da in the pop­u­la­tions stud­ied.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.